211 related articles for article (PubMed ID: 12439596)
1. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
[TBL] [Abstract][Full Text] [Related]
2. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti JA; Kemeny NE; Saltz LB; Huang Y; Tong WP; Chou TC; Sun M; Pulliam S; Gonzalez C
J Clin Oncol; 1996 Mar; 14(3):709-15. PubMed ID: 8622015
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
van Hazel GA; Pavlakis N; Goldstein D; Olver IN; Tapner MJ; Price D; Bower GD; Briggs GM; Rossleigh MA; Taylor DJ; George J
J Clin Oncol; 2009 Sep; 27(25):4089-95. PubMed ID: 19652069
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
Louvet C; André T; Gamelin E; Garcia ML; Saavedra A; Lenaers G; de Gramont A; Méry-Mignard D; Kalla S
Bull Cancer; 2004 Dec; 91(12):279-84. PubMed ID: 15634630
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
16. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
17. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Duffour J; Gourgou S; Desseigne F; Debrigode C; Mineur L; Pinguet F; Poujol S; Chalbos P; Bressole F; Ychou M
Cancer Chemother Pharmacol; 2007 Aug; 60(3):383-9. PubMed ID: 17124595
[TBL] [Abstract][Full Text] [Related]
18. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Luo HY; Li YH; Zhang L; Jiang WQ; Shi YX; Wang F; He YJ; Xu RH
Ai Zheng; 2007 Aug; 26(8):905-8. PubMed ID: 17697557
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
